Battle of the Biotech Unicorns: CureVac vs. Moderna
An interview never seen before. We brought together the founders and CEOs of the two…
Messenger RNA (mRNA) technology is based on the idea that human cells can be used as on-demand factories to develop therapeutic proteins by giving them instructions in the form of mRNA. Although mRNA therapeutics and vaccines could be found in drug development pipelines before Covid-19 emerged, the pandemic suddenly moved the mRNA technology into the limelight.
Now, the world has seen mass vaccinations using mRNA-based vaccines developed by Moderna and Pfizer/BioNTech. But the mRNA technology holds promise for other indications as well, including cancer and rare diseases. Read on to learn how this new technology is moving into the mainstream with an influx of investments and new discoveries.
European Biotech Industry Report 2021
This report discusses how the Covid-19 pandemic impacted Europe’s life science industry and covers recent market trends, investments, and collaborations.
Go to ReportAn interview never seen before. We brought together the founders and CEOs of the two…
AstraZeneca will work with Moderna Therapeutics to bring together to the market an mRNA version of Novartis' failed…
CureVac will be working with pharma giant Eli Lilly in the development of up to…
Biotech is the best source of innovation in R&D, making its companies the darlings of…
Flanders Innovation and Entrepreneurship has given eTheRNA a €1M grant to further improve its TriMix…
You’ve certainly heard about antibodies, peptides and even DNA as therapeutics, but what about RNA?…
AstraZeneca and its R&D arm MedImmune have partnered with Munich-based Ethris to use its mRNA…
CureVac has published proof-of-concept data for an mRNA rabies vaccine that could open the door…
BioNTech has published results from the first clinical trial for an mRNA-based individualized vaccine with…
Sean Marett took a red-eye from New York to speak at Refresh last month: here…
eTheRNA has started a Phase Ib trial in patients with melanoma to test a cancer immunotherapy…
BioNTech has reported a new technology that could overcome some of the most challenging issues…